期刊文献+

鸡支康口服液的亚慢性毒性试验研究 被引量:8

Study on Subchronic Toxicity Test of Jizhikang Oral Liquid
下载PDF
导出
摘要 试验根据《兽药试验技术规范汇编》进行了鸡支康口服液对小白鼠的亚慢性毒性研究,试验设高、中、低3个剂量组,另设空白对照组,连续给药28 d后剖杀各组小鼠,观察其临床表现,并进行血常规和血液生化指标检测及脏器系数和组织病毒学检查。统计学分析结果表明,各组间的体重变化和脏器系数均无显著差异(P>0.05);血常规检查结果表明,试验组的红细胞数、血小板数、红细胞压积及淋巴细胞数与空白对照组相比呈下降趋势,但差异不显著(P>0.05),其余各检测指标各试验组与空白对照组相比差异均不显著(P>0.05);血液生化指标结果表明,试验组的谷丙转氨酶、谷草转氨酶及血糖含量与空白对照组相比呈下降趋势,但差异不显著(P>0.05),其余各检测指标各试验组与空白对照组相比差异均不显著(P>0.05);组织病理学检查结果显示,小鼠的主要内脏器官未见明显异常。试验结果表明,鸡支康口服液对小鼠血常规和血液生化指标影响甚微。提示,其按临床剂量使用无毒性反应,安全可靠。 In order to study the subchronic toxicity of the Jizhikang oral liquid, the test was conducted in accordance with the animal drug technological specification compile of Ministry of Agriculture. Experiment mice were divided into 4 groups, the 3 experiment groups were given Jizhikang oral liquid of 0.01,0.02,0.04 mL/(g·BW) for 28 days. The control group was given the same amount of naomal saline. The results showed that the body weight, organ coefficient, index of hematology and blood biochemistry indices in 3 experiment groups were not significantly different from that in the control group(P〉0.05). Results of histopathology examination showed that it had no adverse reaction in experiment groups. The results showed that the Jizhikang oral liquid had no subchronic toxicity,and could be safely used for experimental animals.
出处 《中国畜牧兽医》 CAS 北大核心 2013年第9期140-143,共4页 China Animal Husbandry & Veterinary Medicine
基金 江苏牧院2012年院级课题(QN1204)
关键词 鸡支康口服液 小鼠 亚慢性毒性试验 Jizhikang oral liquid mice subchronie toxicity test
  • 相关文献

参考文献7

二级参考文献55

  • 1Jone.,RC,王碧林.鸡传染性支气管炎研究进展[J].国外兽医学(畜禽传染病),1996,16(4):11-13. 被引量:2
  • 2蒋雷,费鲜明,苏芳,屠静,周永列.血清球蛋白与慢性丙型肝炎关系的临床研究[J].浙江实用医学,2006,11(5):307-307. 被引量:2
  • 3Wanda M. Haschek. Handbook of Toxicological Pathology [M] . Second Edition, Two-Volume Set, Volume 1-2, 2001: 1266-1335.
  • 4孙家志.三种检测血清ALT方法比较.医学检验与临床,2009,01:95-95.
  • 5Amacher DE. Serum transaminase elevations as indicators of hepatic injuries following the administration of drugs [J] . Regul Toxicol Pharmacol, 1998, 27:119- 130.
  • 6Kaplowitz N. Drug-induced liver disorders: implication for drug development and regulation. [J]. Drug Saf, 2001, 24: 483-490.
  • 7Health Canada Scientific Advisory Panel on Hepatotoxicity. Draft Recommendations from the Scientific Advisory Panel Sub-groups on Hepatotoxicity[N/OL] . Hepatotoxicity of Health Products. Ottawa, Canada: Health Canada;2004. Available at: http://www. hc-sc.gc. ca/hpfb-dgpsa/ tpddpt/sap_ h _ 2004-07-26 _ dp v6 e. html. Accessed July 11, 2005.
  • 8EMEA. Concept Paper on the Development of a Committee for Medicinal Products for Human Use (CHMP) Guideline on Detection of Early Signals for Hepatotoxicity.from Non-Clinical Documentation[N/OL].2004. London, UK: European Agency for the Evaluation of Medicinal Products. Available at: http: //www. emea. eu. int/pdfs/human/ swp/001004en.pdf. Accessed July 11, 2005.
  • 9Weingand K, Brown G, Hall R, et al. Harmonization of animal clinical pathology testing in toxicity and safety studies[J]. Fundam Appl Toxicol, 1996, 29: 198-201.
  • 10Dufour D R, Lott J A, Nolte FS, et al. Diagnosis and monitoring of hepatic injury [J] . performance characteristics of laboratory tests.Clin Chem, 2000, 46:2027- 2049.

共引文献69

同被引文献61

引证文献8

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部